ArticleJournal of hematology & oncology2019

Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.

Liwei Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.